Skip to main content
HR 2296 116th Congress House Health Civil actions and liability Congressional oversight Consumer affairs Corporate finance and management Government information and archives Government studies and investigations Inflation and prices Medical research Prescription drugs Research and development

More Efficient Tools to Realize Information for Consumers Act

Introduced: April 12, 2019 Introduced by: Schakowsky, Janice D. Democratic · Illinois See on congress.gov
 Everywhere this bill has been 10 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Sep 24, 2019
Placed on the Union Calendar, Calendar No. 170.
Sep 24, 2019
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-215.
Jul 17, 2019
Ordered to be Reported (Amended) by Voice Vote.
Jul 17, 2019
Committee Consideration and Mark-up Session Held.
Jul 11, 2019
Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
Jul 11, 2019
Subcommittee Consideration and Mark-up Session Held.
May 21, 2019
Subcommittee Hearings Held.
Apr 15, 2019
Referred to the Subcommittee on Health.
Apr 12, 2019
Referred to the House Committee on Energy and Commerce.
Apr 12, 2019
Introduced in House
 Plain-English summary Congressional Research Service

More Efficient Tools to Realize Information for Consumers Act or the METRIC Act

This bill requires prescription drug manufacturers to report, and the Department of Health and Human Services (HHS) to publish, specified information related to prescription drug pricing and the pharmaceutical supply chain. Specifically, HHS must publish reports submitted by drug manufacturers that include the percentage of any wholesale drug price increase that is greater than 10% in one calendar year (or 25% over three consecutive years), an explanation for the price increase, and other data. HHS must enter agreements with other agencies, research organizations, and public and private health insurers to share data submitted to HHS by drug manufacturers about the identity and quantity of drug sample requests by health practitioners.

HHS also must publish online aggregate data reported by pharmacy benefits managers (PBMs), including the percentage of prescriptions provided by mail-order, rate that generic versions of drugs are dispensed, and aggregate discounts, rebates, or price concessions negotiated.

The bill requires the Federal Trade Commission to report about potentially anticompetitive practices by PBMs such as steering patients to certain pharmacies or designing price formulas that increase the market share of higher priced drugs, among other information. The report also must include recommendations to increase transparency and deter anticompetitive behavior.

The bill further requires Medicare prescription drug plan sponsors to implement an electronic, real-time benefit tool that provides prescribers with patient-specific formulary and benefit information. Additionally, the bill expands certain price reporting requirements for prescription drug payments under Medicare.

What's happening now September 24, 2019

Placed on the Union Calendar, Calendar No. 170.

 Committees of jurisdiction 2